# Small Molecule Drugs Sector

Canonical URL: https://biopharmsignal.com/sector/small-molecule-drugs

Small Molecule Drugs includes companies developing orally available or otherwise chemically synthesized medicines built from relatively low-molecular-weight compounds. This remains one of the broadest and most commercially important categories in biotech and pharma.

Companies currently grouped under Small Molecule Drugs: 36

## Recent Sector News

- 2026-07-20 07:00 EST — GSK — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — GSK — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-15 13:40 EST — GSK — [GSK completes acquisition of Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-nuvalent-inc-c44954f4) — Source: GSK plc
- 2026-07-14 12:00 EST — IKT — [Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-its-at-th-30edf4cb) — Source: Inhibikase Therapeutics
- 2026-07-14 08:00 EST — ACXP — [Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection](https://biopharmsignal.com/news/ACXP/acurx-pharmaceuticals-announces-scientific-poster-presentation-of-ibezapolstat-s-7d80a5a2) — Source: Acurx Pharmaceuticals
- 2026-07-13 07:00 EST — GSK — [Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer](https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi--18610cf7) — Source: GSK plc
- 2026-07-10 11:00 EST — GSK — [GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-b379a2b1) — Source: GSK plc
- 2026-07-09 10:00 EST — GSK — [Roy Jakobs to join GSK Board as Non-Executive Director](https://biopharmsignal.com/news/GSK/roy-jakobs-to-join-gsk-board-as-non-executive-director-560f2019) — Source: GSK plc
- 2026-07-08 08:00 EST — ACXP — [Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update](https://biopharmsignal.com/news/ACXP/acurx-pharmaceuticals-to-discuss-second-quarter-2026-financial-results-on-august-1f2a139a) — Source: Acurx Pharmaceuticals
- 2026-07-06 13:30 EST — CRIS — [Curis Consents First Six Patients in TakeAim CLL Study](https://biopharmsignal.com/news/CRIS/curis-consents-first-six-patients-in-takeaim-cll-study-45969449) — Source: Curis Inc
- 2026-07-03 11:30 EST — KURA — [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-32057cde) — Source: Kura Oncology
- 2026-07-02 20:01 EST — IKT — [Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-56-d71ac313) — Source: Inhibikase Therapeutics
- 2026-07-02 11:00 EST — BCRX — [BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-afb4cc8d) — Source: BioCryst Pharmaceuticals
- 2026-06-30 12:00 EST — MNOV — [MediciNova CEO Provides Shareholder Update](https://biopharmsignal.com/news/MNOV/medicinova-ceo-provides-shareholder-update-9776ffac) — Source: MediciNova
- 2026-06-29 11:00 EST — BCRX — [BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility](https://biopharmsignal.com/news/BCRX/biocryst-sharpens-scientific-focus-on-external-innovation-with-wind-down-of-inte-83b84c41) — Source: BioCryst Pharmaceuticals
- 2026-06-26 13:42 EST — CRIS — [Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split](https://biopharmsignal.com/news/CRIS/curis-announces-eleven-active-clinical-sites-in-takeaim-cll-study-reaffirms-pati-978d906e) — Source: Curis Inc
- 2026-06-25 13:46 EST — GSK — [GSK announces commencement of tender offer to acquire Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-announces-commencement-of-tender-offer-to-acquire-nuvalent-inc) — Source: GSK plc
- 2026-06-25 13:46 EST — ENTA — [Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-partner-abbvie-receives-european-commission-approval-of-maviretr-glecaprevir-pibrentasvir-for-people-with-acute-hepatitis-c-virus) — Source: Enanta Pharmaceuticals
- 2026-06-25 13:46 EST — EXEL — [Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer](https://biopharmsignal.com/news/EXEL/exelixis-provides-update-on-the-phase-3-stellar-303-trial-evaluating-zanzalintinib-in-combination-with-an-immune-checkpoint-inhibitor-in-patients-with-metastatic-colorectal-cancer) — Source: Exelixis
- 2026-06-25 13:46 EST — INVA — [Nortiva Bio Launches to Develop Long-Acting Oral Medicines](https://biopharmsignal.com/news/INVA/nortiva-bio-launches-to-develop-long-acting-oral-medicines) — Source: Innoviva

## Companies

- [ACXP](https://biopharmsignal.com/company/ACXP) — Acurx Pharmaceuticals
- [FOLD](https://biopharmsignal.com/company/FOLD) — Amicus Therapeutics
- [ARDX](https://biopharmsignal.com/company/ARDX) — Ardelyx
- [AZN](https://biopharmsignal.com/company/AZN) — AstraZeneca PLC
- [BCYC](https://biopharmsignal.com/company/BCYC) — Bicycle Therapeutics
- [BCRX](https://biopharmsignal.com/company/BCRX) — BioCryst Pharmaceuticals
- [BMEA](https://biopharmsignal.com/company/BMEA) — Biomea Fusion
- [CCCC](https://biopharmsignal.com/company/CCCC) — C4 Therapeutics
- [CDXI](https://biopharmsignal.com/company/CDXI) — Cardax Pharma
- [CRVS](https://biopharmsignal.com/company/CRVS) — Corvus Pharmaceuticals
- [CRIS](https://biopharmsignal.com/company/CRIS) — Curis Inc
- [LLY](https://biopharmsignal.com/company/LLY) — Eli Lilly
- [ENTA](https://biopharmsignal.com/company/ENTA) — Enanta Pharmaceuticals
- [EPIX](https://biopharmsignal.com/company/EPIX) — ESSA Pharma
- [EXEL](https://biopharmsignal.com/company/EXEL) — Exelixis
- [FGEN](https://biopharmsignal.com/company/FGEN) — FibroGen
- [FULC](https://biopharmsignal.com/company/FULC) — Fulcrum Therapeutics
- [GTHX](https://biopharmsignal.com/company/GTHX) — G1 Therapeutics
- [GSK](https://biopharmsignal.com/company/GSK) — GSK plc
- [IKT](https://biopharmsignal.com/company/IKT) — Inhibikase Therapeutics
- [INVA](https://biopharmsignal.com/company/INVA) — Innoviva
- [JNJ](https://biopharmsignal.com/company/JNJ) — Johnson & Johnson
- [KALV](https://biopharmsignal.com/company/KALV) — KalVista Pharmaceuticals, Inc.
- [KURA](https://biopharmsignal.com/company/KURA) — Kura Oncology
- [KYMR](https://biopharmsignal.com/company/KYMR) — Kymera
- [MNOV](https://biopharmsignal.com/company/MNOV) — MediciNova
- [NRIX](https://biopharmsignal.com/company/NRIX) — Nurix Therapeutics
- [OCUP](https://biopharmsignal.com/company/OCUP) — Ocuphire
- [OMER](https://biopharmsignal.com/company/OMER) — Omeros
- [PMVP](https://biopharmsignal.com/company/PMVP) — PMV Pharmaceuticals
- [TERN](https://biopharmsignal.com/company/TERN) — Terns Pharmaceuticals
- [VTYX](https://biopharmsignal.com/company/VTYX) — Ventyx Biosciences, Inc.
- [VRTX](https://biopharmsignal.com/company/VRTX) — Vertex Pharmaceuticals Incorporated
- [VTRS](https://biopharmsignal.com/company/VTRS) — Viatris Inc.
- [XFOR](https://biopharmsignal.com/company/XFOR) — X4 Pharmaceuticals
- [ZNTL](https://biopharmsignal.com/company/ZNTL) — Zentalis